Intraocular pressure changes after switching to the LTFC for each of the previous medication classes (mm Hg, mean (SD))
| Sample | Baseline | Treated | Difference | p Value | |
|---|---|---|---|---|---|
| Monotherapy | |||||
| Latanoprost | 69 | 20.8 (3.4) | 17.8 (2.9) | −3.1 (3.6) | <0.001 |
| Timolol | 53 | 21.6 (4.3) | 17.9 (2.3) | −3.7 (4.5) | <0.001 |
| Dorzolamide or brinzolamide | 33 | 22.1 (4.4) | 17.4 (2.2) | −4.7 (3.5) | <0.001 |
| Brimonidine | 18 | 20.2 (4.2) | 16.6 (2.8) | −3.6 (3.6) | <0.001 |
| Adjunctive therapy | |||||
| Dorzolamide/timolol | 505 | 21.1 (3.8) | 17.8 (3.1) | −3.4 (3.4) | <0.001 |
| Latanoprost + timolol | 342 | 19.4 (3.8) | 17.7 (3.1) | −1.7 (3.6) | <0.001 |
| Pilocarpine/timolol | 159 | 21.3 (3.3) | 17.5 (2.6) | −3.8 (3.5) | <0.001 |
| Latanoprost + β blocker | 86 | 19.2 (3.5) | 17.6 (2.5) | −1.6 (3.5) | <0.001 |
| Brimonidine + β blocker | 56 | 21.3 (3.7) | 17.2 (2.8) | −4.1 (3.2) | <0.001 |
| Pilocarpine + metipranolol | 56 | 21.7 (3.7) | 17.6 (2.8) | −4.0 (3.5) | <0.001 |
| Latanoprost + brimonidine | 52 | 20.0 (3.3) | 18.2 (2.6) | −1.8 (3.0) | <0.001 |
| Dorzolamide + timolol | 50 | 21.1 (3.1) | 18.0 (2.9) | −3.1 (3.2) | <0.001 |
| Brinzolamide + timolol | 45 | 20.5 (3.4) | 17.9 (3.5) | −2.6 (2.9) | <0.001 |
| Latanoprost + dorzolamide/timolol | 38 | 19.9 (4.0) | 19.0 (3.6) | −0.9 (4.1) | 0.1792 |
| Latanoprost + brinzolamide | 34 | 19.7 (4.4) | 17.0 (3.2) | −2.7 (4.1) | <0.001 |
| Brimonidine + CAI | 24 | 20.9 (2.9) | 17.5 (2.1) | −3.3 (3.5) | <0.001 |
| Pilocarpine + timolol | 21 | 21.9 (2.8) | 17.8 (2.6) | −4.1 (3.5) | <0.001 |
| Latanoprost + dorzolamide | 20 | 20.2 (3.8) | 17.8 (3.3) | −2.4 (3.6) | 0.007 |
| Travoprost + timolol | 15 | 22.0 (3.8) | 16.9 (3.2) | −5.1 (5.5) | <0.001 |